Abstract
The progressive neurodegenerative process in Parkinson's disease (PD) is not restricted to dopaminergic midbrain neurons but involves the entire nervous system. In this review, we outline established treatment options at different disease stages and address new therapeutic approaches. These include, based on recent advances in the understanding of the pathophysiology of PD, genetic and disease-modifying approaches to reduce abnormal accumulation and aggregation of alpha-synuclein (aSYN), mitochondrial dysfunction, and dysfunction of lysosomal proteins. Moreover, we highlight clinical trials to reduce neuroinflammation and increase neurorestoration.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Clinical Pharmacology and Therapeutics |
| Jahrgang | 105 |
| Ausgabenummer | 5 |
| Seiten (von - bis) | 1106-1120 |
| Seitenumfang | 15 |
| ISSN | 0009-9236 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.05.2019 |
Fördermittel
K.E.Z. has received research support from an intramural grant from the Christian-Albrechts University of Kiel, from the Benign Essentail Blepharospasm Foundation, and with an unrestricted grant from Ipsen. She has received lecture fees from Allergan, Merz, and Bayer. She has served as a consultant and received fees from Merz and Ipsen. E.S. has received intramural research funding from the University of Kiel and reports speaker’s honoraria from Bayer Vital GmbH and AbbVie outside the submitted work. F.H. received grants from the German Research Council (DFG) and intramural funding from the Christian-Albrechts University of Kiel. N.B. has received research funding from the German Research Foundation (BR 4328/2-1), the Collaborative Center for X-linked Dystonia-Parkinsonism and the Else-Kröner Fresenius Stifung (2017_HA17). He has received speaker’s honoraria from Grünenthal, TEVA, and UCB and a travel grant from Bayer. D.B. has received grants from the Michael J. Fox Foundation, Janssen Pharmaceutica N.V., German Parkinson’s Disease Association (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, TEVA Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and Damp foundation. She served as a consultant for Biogen, BIAL, Lundbeck, and UCB Pharma GmbH. She has received personal fees from AbbVie, Biogen, BIAL, Lundbeck, and UCB Pharma GmbH Zambon.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen -
SDG 10 – Weniger Ungleichheiten
Strategische Forschungsbereiche und Zentren
- Querschnittsbereich: Medizinische Genetik
Fingerprint
Untersuchen Sie die Forschungsthemen von „Progress of Pharmacological Approaches in Parkinson's Disease“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver